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SUMMARY
The lack of knowledge about the mechanism of erythrocyte biogenesis through self-replication makes the in vitro generation of large
quantities of cells difficult. We show that transduction of c-MYC and BCL-XL into multipotent hematopoietic progenitor cells derived
frompluripotent stem cells and gene overexpression enable sustained exponential self-replicationof glycophorin A+ erythroblasts, which
we term immortalized erythrocyte progenitor cells (imERYPCs). In an inducible expression system, turning off the overexpression of
c-MYC and BCL-XL enabled imERYPCs to mature with chromatin condensation and reduced cell size, hemoglobin synthesis, downregu-
lation ofGCN5, upregulation ofGATA1, and endogenous BCL-XL and RAF1, all of which appeared to recapitulate normal erythropoiesis.
imERYPCs mostly displayed fetal-type hemoglobin and normal oxygen dissociation in vitro and circulation in immunodeficient mice
following transfusion. Using critical factors to induce imERYPCs provides a model of erythrocyte biogenesis that could potentially
contribute to a stable supply of erythrocytes for donor-independent transfusion.
INTRODUCTION
Blood transfusion for patients with severe anemia depends
on blood donations. However, factors such as declining
birth rates, an aging population, and viral contamination
are all associated with reductions in the availability of
donor blood. It was once expected that CD34+ cells from
cord blood (CB) or bone marrow would someday provide
a means for ex vivo expansion or in vitro generation of
erythrocytes (red blood cells; RBCs) for transfusion (Giarra-
tana et al., 2011), but the inability to produce sufficient
numbers of CD34+ cells remains a bottleneck in this pro-
cess. It was also thought that the advent of pluripotent
stem cells (PSCs), including embryonic stem cells (ESCs)
and induced pluripotent stem cells (iPSCs), would elimi-
nate the need for blood donation, but a series of differenti-
ation trials to create various blood cells from human ESCs
or iPSCs has highlighted the difficulty of obtaining blood
cells in quantities sufficient for use in transfusion using
this method (Lu et al., 2007, 2011; Takayama et al., 2008,
2010).
In hematopoietic systems, individual blood progenitor
cells each appear to have their own proliferation program
with ‘‘self-replication potential.’’ Identification of the self-
replication factors in lineage blood progenitors should
enable immortalization of the cells. With that in mind,
we have been developing a system based on the concept
that immortalized progenitor cells can be created through
self-replication. We recently observed that overexpression
(O/E) of c-MYC in hematopoietic progenitor cells (HPCs)
derived from human PSCs induces transient growth of
the megakaryocyte-erythrocyte progenitor (MEP) popula-
tion (Hirata et al., 2013; Takayama et al., 2010). Therefore,
with the aim of generating large quantities ofmature eryth-
rocytes, we endeavored to determine the conditions for
using a combination of c-MYC and related gene candidates
to induce a self-replicating erythrocyte lineage at an imma-
ture stage.
RESULTS AND DISCUSSION
Creation of a Self-Replicable Erythrocyte-Producing
Cell Line from Human PSCs
Because MEPs divide into erythrocytes and megakaryo-
cytes (MKs) depending on the actions of specific transcrip-
tional factors and cytokines (Hirata et al., 2013), we
suspected that O/E of c-MYC plus erythropoietin (EPO)
could be specific for erythrocyte self-replication. As ex-
pected, in the presence of EPO plus stem cell factor (SCF),
O/E of c-MYC (but not mock) in HPCs derived from human
ESCs (KhES-3) promoted proliferation of glycophorin A
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Figure 1. c-MYC and BCL-XL Are Self-Replication Factors for Erythrocyte Progenitors Derived from Human PSCs
(A) Numbers of glycophorin A (GPA)+ cells transduced with c-MYC on days 0, 14, and 21.
(B) Expression of BCL-XL in cells transduced with vehicle (mock) or a c-MYC overexpression vector.
(C) Numbers of GPA+ cells transduced with c-MYC alone, BCL-XL alone, or a combination of c-MYC plus BCL-XL on days 12, 18, and 28.
(legend continued on next page)
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(GPA)+ cells. This growth advantage was only transient and
disappeared 14 days after transduction (Figure 1A), which
was caused by an increment in annexin+ cells in the
c-MYC-transfected erythrocytes, which we observed previ-
ously in c-MYC-transfected MKs (Takayama et al., 2010).
However, growth was followed by an apoptosis event also
caused by the O/E of c-MYC. The caspase family negatively
regulates BCL family genes (Martinou and Youle, 2011). Of
these, Bcl-xl/BCL-XL is reportedly suppressed by elevated
c-MYC (Jayapal et al., 2010). Consistent with that report,
we observed that BCL-XL mRNA levels were reduced in
c-MYC transductants (Figure 1B). We therefore sought to
prevent apoptosis through O/E of c-MYC plus BCL-XL in
KhES-3-derived HPCs.
Transduction of c-MYC plus BCL-XL, but not c-MYC or
BCL-XL individually, appeared to induce exponential
growth that persisted for about a month (Figure 1C). Cells
cotransfected with c-MYC and BCL-XL showed 5.4 times
higher BCL-XL expression (Figure 1D) and a smaller
annexin+ fraction (Figure 1E) than cells transfected with
c-MYC alone, indicating that BCL-XL contributed to an
antiapoptotic effect in c-MYC-transfected erythroblasts.
To select stably proliferative clones over that period, we
isolated cloned colonies using semisolid medium from
day 12 to day 24 of culture (Figure 1F). During this clonal
selection phase, we confirmed that only cells overexpress-
ing c-MYC plus BCL-XL generated hematopoietic colonies
in semisolid cultures (Figure S1A available online). Fig-
ure 1G depicts two independent clones in the clonal
expansion phase. Both clones exhibited exponential
growth (doubling times: clone 8, 36.8 hr; clone 16,
48.1 hr) for over 6 months. In addition, over 99% of the
population expressed GPA and CD71, two phenotypic sur-
face markers of erythroblasts found on erythrocytes
derived directly from ESCs or cord blood cells (Figure 1H;
unpublished data). We therefore named these cells immor-
talized erythrocyte progenitor cells (imERYPCs). The
selected clones showed a dependency on EPO for growth
but did not require SCF (Figure S1B) or feeder cells (Fig-
ure S1C), and they exhibited similar growth curves before
and after cryopreservation (Figure S1D). Using this gene
set, we generated stably proliferatingGPA+ erythrocyte pro-
genitors from human iPSCs (Figures S1E and S1F). From
these results, we conclude that c-MYC and BCL-XL are
key mediators conferring self-replication potential on
erythrocyte progenitors derived from human PSCs.
ImERYPCs Are Capable of Differentiating to a Mature
State with Heme Synthesis and Oxygen-Carrying
Capability
We established two imERYPC clones, clone 8 and 16, that
showed exponential cell growth (Figure 2A, DOX+). Inter-
estingly, after turning genes off using a doxycycline
(DOX)-inducible system, the imERYPCs stopped growing
(Figure 2A, DOX) and exhibited dramatic changes in
morphology within 7 days after genes were turned off,
going from basophilic immature erythroblasts to mature
polychromatic/orthochromatic erythroblasts with chro-
matin condensation (Figures 2B and S2A), which was also
seen with iPSC-derived imERYPCs (Figure S1G). Seven
days after genes were turned off, 47%–52% of imERYPCs
were polychromatic and 43%–50% were orthochromatic
erythroblasts with 0.36% enucleation. By contrast, over
80% of cells with genes turned on were proerythroblasts
(Figure S2A).
In imERYPCs with genes turned on, transmission elec-
tron microscopy (TEM) showed a relatively large nucleus
with hypocondensed chromatin and mitochondria (Fig-
ure 2Ci). Downregulation of the genes induced mito-
chondrial aggregation, an increment in endosomal
vacuoles (Figure 2Cii), and chromatin condensation in
more mature imERYPCs (Figure 2Ciii). These changes,
along with the morphological changes observed with
Giemsa staining, reflect the physiological erythrocyte
maturation phase (Simpson and Kling, 1967; Keerthiva-
san et al., 2010).
The imERYPC cell pellet was red 7 days after genes were
turned off, reflecting heme synthesis (Figure 2D). O-diani-
sidine staining revealed that the fraction of heme+ erythro-
blasts gradually increased after genes were turned off,
ultimately reaching 100% (Figures 2E and S2B). At this
stage, the average imERYPC contained 30.0 ± 3.0 (clone
8) or 37.4 ± 4.1 (clone 16) pg of hemoglobin. This is com-
parable to peripheral-blood-derived RBCs (PB-RBCs),
(D and E) Expression of BCL-XL (D) and the annexin+ cell fraction (E) among cells transduced with c-MYC alone or c-MYC plus BCL-XL. Data in
(A)–(E) represent the mean ± SE from three independent experiments.
(F) Schematic diagram of immortalized erythrocyte progenitor cell (imERYPC) induction from human PSCs. Hematopoietic progenitor cells
(HPCs) within ES/iPS sacs were collected and transduced with c-MYC and BCL-XL using doxycycline (DOX)-inducible lentiviral vectors. The
cells were then expanded for 12 days (induction phase). For clonal selection, on day 12 of culture, the cells were transferred to semisolid
culture medium containing DOX and cultivated for an additional 12 days (clonal selection phase). The hematopoietic clones were then
picked up and cultured separately for several months (clonal expansion phase).
(G) Numbers of GPA+ cells derived from two highly proliferative imERYPC clones (clones 8 and 16) from day 50 to day 80 of culture. These
clones grew exponentially for several months.
(H) Dot plots showing imERYPC clone 8 derived from human ESCs. Left panel: x axis, GFP; y axis, GPA. Right panel: x axis, CD71; y axis, GPA.
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which contain about 30 pg of hemoglobin per cell (Rappaz
et al., 2008).
Human PSC-derived erythroblasts reportedly mainly ex-
press g-globin, but also express small amounts of b- and
ε-globin (Ma et al., 2008). To examine the globin types ex-
pressed in imERYPCs, we performed cation exchange
high-performance liquid chromatography (CE-HPLC) and
quantitative PCR (qPCR). In CE-HPLC, the majority of the
hemoglobin in imERYPCs (DOX) was hemoglobin F
(HbF; a2g2), though small amounts of hemoglobin A
(HbA; a2g2) and hemoglobin E (HbE; a2ε2) were also pre-
sent (Figure 2F; imERYPC-8: HbA, 4.5%; HbE, 18.4%;
imERYPC-16: HbA, 5.8%, HbE 2.6%). Additional qPCR
analysis showed the g-globin level in imERYPCs to be
similar to that in CB-derived erythrocytes (CB-RBCs) (Fig-
ure S2C), where HbF (a2g2) was the major type. Both
imERYPC clone 8 and 16 expressed more ε-globin and less
b-globin than CB-RBCs, but the levels remained minor
fractions. These findings confirmed that imERYPCs pro-
duce fetal-type erythroblasts comparable to CB erythro-
blasts and have oxygen delivery capabilities (Figure 2G).
imERYPC-derived erythrocytes (DOX) showed oxygen
dissociation curves (ODCs) similar to those of the CB-
or PB-RBCs (Figure 2G; p50: PB, 27.2 mmHg; CB,
22.1 mmHg; imERYPCs, 27.0 mmHg or 25.7 mmHg,
n = 3). Thus, HbF composed of a- and g-globins is themajor
hemoglobin in imERYPCs.
The Transcriptional Program in ImERYPCs Traces
Normal Erythrocyte Differentiation
We confirmed that, after genes were turned off, imERYPCs
trace the physiological erythroblast differentiation phases
(e.g., chromatin condensation and hemoglobin synthesis).
To compare the transcriptional program operating during
imERYPC differentiation to that operating in physiological
erythroblasts, we used qPCR to assess the time dependence
of the expression of c-MYC and BCL-XL along with GATA1,
RAF1, and GCN5 in imERYPCs (Figures 3A–3E) and CB-
derived erythroblasts (Figures 3F–3J). After turning off
exogenous c-MYC and BCL-XL, total c-MYC levels fell to
one-tenth of that seen when overexpression was induced
(Figure 3A), whereas total BCL-XL was upregulated as
much as 20-fold, as compared to the overexpression state
(Figure 3B), indicating elevated expression of endogenous
BCL-XL. In fact, endogenous BCL-XL expression was ulti-
mately augmented up to 45-fold once the exogenous
gene was silenced (Figures S3A and S3B). The quick down-
regulation of c-MYC from the earlier overexpression stage
may initiate the upregulation of GATA1 and endogenous
BCL-XL and RAF1 (Figures 3C, 3D, and S3A) for heme syn-
thesis (Hafid-Medheb et al., 2003; Haughn et al., 2003).
This schememight also accelerate the parallel downregula-
tion of GCN5 (Figure 3E), contributing to chromatin
condensation (Jayapal et al., 2010). Intriguingly, these
expression patterns were consistent with the temporal
changes in gene expression seen in proliferative immature
erythroblasts (Figure S3C, days 3–9) and nondividing
mature erythroblasts (Figure S3C, days 12–18) derived
from human cord blood CD34+ cells (Figures 3F–3J and
S3C). We therefore conclude that during differentiation
to mature erythrocytes, the transcriptional program oper-
ating in imERYPCs is similar to that in their human eryth-
rocyte equivalents (Figure 3).
Enucleated imERYPCs Are Capable of Intact
Circulation In Vivo
Wenext sought toexamine the invivo functionalityofcircu-
lating imERYPCs, since they seemingly have the capacity to
deliver oxygen in vitro. To date, there are no well-estab-
lished, in vivo models for evaluating transfusion of human
erythrocytes. When 13 109 human PB-RBCs were intraper-
itoneally infused into nonobese diabetic (NOD) severe
combined immunodeficiency (SCID) interleukin 2Rg (IL-
2Rg) null (NOG) mice with irradiation-induced anemia,
Figure 2. Immortalized Erythrocyte Progenitor Cells Can Be Differentiated into Functional Erythroblasts Exhibiting Hemoglobin
Synthesis and Chromatin Condensation after Genes Are Turned Off
(A) Numbers of the cells obtained from clones 8 and 16 cultured for 7 days in the presence or absence of DOX. The cells stopped growing
when DOX was absent. Results are expressed as means ± SE from four independent experiments.
(B) Photomicrographs showing representative Giemsa staining of imERYPC clone 8 in the presence of DOX or 2, 4, and 7 days after DOX off.
(C) Transmission electron micrographs of imERYPC with DOX on (i) or 5 days after DOX off (ii and iii). Arrows indicate a mitochondrion.
Arrowheads indicate chromatin condensation. Asterisks indicate endosomal vacuoles.
(D) Pictures showing representative imERYPC clone 8 pellets obtained in the presence or absence of DOX. In the absence of DOX, cells
generate heme and show the characteristic red color.
(E) Percent heme-positive cells obtained 7 days after DOX withdrawal. Results are expressed as means ± SE from four independent ex-
periments.
(F) Chromatograms showing CE-HPLC analyses of hemoglobin generated in imERYPC clones 8 and 16.
(G) Oxygen dissociation curves (ODCs) for adult erythrocytes derived from peripheral blood (PB-erythrocyte) and fetal erythrocytes
differentiated from cord blood CD34+ cells (CB-erythrocyte) in imERYPC clone 8 and clone 16.
(F) and (G) show representative data from three independent experiments.
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circulating levels peaked at less than 1.0% after 24 hr and
then quickly declined (Figure 4A). We therefore sought to
optimize the mouse model used to assess human erythro-
cyte transfusion. Earlier reports of erythrocyte transfusion
into NOG mice suggested the efficacy of using infused PB-
RBCs as a decoy (Giarratana et al., 2005, 2011; Jime´nez-
Dı´az et al., 2009) or injecting clodronate-liposomes to
deplete macrophages in vivo (Arnold et al., 2011; Hu
et al., 2011). We therefore tested the effect of clodronate-
liposomes on imERYPC circulation in mice pretreated
with decoy RBCs.
NOG mice were irradiated with 2 Gy to induce anemia
and were administered 2 3 109 PB-RBCs 13 days later as a
decoy plus clodronate-liposomes (1 mg/body) or PBS. After
an additional 24hr, 13 109 imERYPCs stainedwith carbox-
yfluorescein diacetate succinimidyl ester (CFSE) were
administered intraperitoneally (Figure 4B). Samples
collected from the retro-orbital plexus on days 1, 3, 5,
Figure 3. Quantitative PCR Analysis dur-
ing the Course of imERYPC and CB-Derived
Erythroblast Maturation
Time course of changes in the expression of
total c-MYC, total BCL-XL, GATA1, RAF1, and
GCN5 in imERYPCs after genes were turned
off (A–E) or CB-erythroblasts (F–J). Black
and blue bars represent clones 8 and 16,
respectively, in (A)–(E). Results are ex-
pressed as means ± SE from four indepen-
dent experiments.
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Figure 4. In Vivo Circulation and Enucleation of Immortalized Erythrocyte Progenitor Cells in NOG Mice
(A) Representative dot plots showing the chimerism of human PB-RBCs in NOD/SCID/IL-2Rg null (NOG) mice. A total of 13 109 RBCs were
transfused intraperitoneally, after which PB samples were collected on days 1, 2, and 3.
(B) Schematic diagram of imERYPC transfusion into NOG mice. NOG mice irradiated with 2 Gy were intravenously administered clodronate-
liposomes (1 mg/body, n = 6 from three independent experiments) or PBS (n = 6 from three independent experiments) and transfused
(legend continued on next page)
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and 7 after imERYPC administration confirmed the pres-
ence of circulating imERYPC erythrocytes, and although
the efficiency remained low, it was augmented by clodro-
nate-liposomes (Figures 4C and 4D). We noticed that
nearly all of the imERYPCs circulating in the peripheral
blood were enucleated (Figures 4E, 4F, and S4A), whereas
the enucleation rate before transfusion was only 0.36% ±
0.03%, which suggests that enucleated and deformable
erythrocytes might selectively circulate. Moreover, circula-
tion of enucleated imERYPCs was slightly increased at
7 days, suggesting that only enucleated cells have in vivo
circulation potential.
Alternatively, the low circulation rate might be caused by
injury to imERYPCs in vitro, whichwould then be removed
from the body within 2 hr after transfusion (Hod et al.,
2010). To test that possibility, human PB-RBCs (100%
enucleated) and carboxyfluorescein succinimidyl ester
(CSFE)-labeled imERYPCs (>99% nucleated) were simulta-
neously infused intraperitoneally to clodronate-pretreated
NOG mice, after which the chimerism was examined (Fig-
ure S4B). CSFE human RBCs and CSFE+ imERYPCs each
peaked at around 24 hr, and the circulation was then
observed for 120 hr, although the chimerism differed be-
tween the two groups (PB-RBCs: 0.1%–0.2%, imERYPCs:
0.01%; Figure S4C). These results show that although the
number of PB-RBCs was 10-fold higher than imERYPCs,
the kinetics of their chimerism were consistently similar
(Figure S4C). This indicates that the lower in vivo rate of
imERYPCcirculation isduenot to rapid removalbutpossibly
to the lower rate of enucleation before transplantation.
In this study, we demonstrated that distinct features of
c-MYC activation definitely control the proliferation stage
at the progenitor level or the subsequent maturation stage,
indicating c-MYC is a fate-determinant factor in erythro-
cytes derived fromhuman PSCs (Acosta et al., 2008; Jayapal
et al., 2010; Rylski et al., 2003). We also demonstrated that
the distinct pattern of BCL-XL expression (i.e., lower dur-
ing the proliferation phase and higher during the differen-
tiation phase) supports erythrocyte maturation (Figures 3B
and S3A), which is consistent with earlier reports (Hafid-
Medheb et al., 2003; Haughn et al., 2003; Motoyama
et al., 1995; Wagner et al., 2000).
Recent pioneering work produced the successful induc-
tion of a human iPSC-derived immortalized erythroid pro-
genitor cell line and a humanCB-derived erythroid progen-
itor cell line through transduction of HPV16-E6/E7 (Kurita
et al., 2013). However, HPV16-E6/E7 causes uterocervical
cancer and exerts a variety of oncogenic effects (zur Hau-
sen, 2002). Moreover, HPV16-E6/E7 is not normally
expressed in human cells and potentially changes the char-
acter of the cells. On the other hand, imERYPCs were estab-
lished through transient activation of c-MYC and BCL-XL,
originally expressed in endogenous erythrocyte progeni-
tors, reflecting the physiological machinery of cell prolifer-
ation along with physiological characteristics, which
contributes to the safety of clinical application.
We have calculated that, theoretically, direct differentia-
tion from undifferentiated hiPSCs would require around
1,000–2,000 l of culture to produce 1 unit of RBCs (1 3
1012 cells), whereas less than 50–100 l of culture might be
sufficient using a system of imERYPCs. In addition,
imERYPCs are cultured in suspension without feeder cells
and are easily manipulated, and a master cell stock of
imERYPCs provides sufficient numbers of erythrocytes in
a shorter period than hiPSCs. This scale is consistent with
the imERYPC growth curve, even after thawing cells from
cryopreservation (Figure S1). This strongly suggests that,
with more efficient enucleation, master cell and working
cell systems using imERYPCs have the potential to achieve
a more constant and safer supply of RBCs for transfusion.
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intraperitoneally with 2 3 109 human peripheral RBCs 13 days after irradiation. Then 24 hr later they received 1 3 109 imERYPCs with
5 days of DOX off (clone 8) labeled with CFSE. Peripheral blood samples were then collected on days 1, 3, 5, and 7 after imERYPC transfusion.
(C) Representative dot plots showing the circulation chimerism of imERYPCs (CSFE+) in mice treated with or without clodronate-liposomes.
(D) Peripheral blood chimerism of imERYPCs on days 1, 3, 5, and 7 after transfusion. Black and blue bars represent the circulation rates in
mice treated with (blue bars) or without (black bars) clodronate-liposomes. Results are expressed as means ± SE.
(E) Representative Giemsa staining of sorted imERYPCs from mice treated with clodronate-liposomes.
(F) Percent enucleation of circulating imERYPCs in mice. The enucleation ratios were calculated as Hoechst-negative cells per total CSFE+
imERYPCs. Results are expressed as means ± SE.
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